13F Holdings
中文EN

ETST Earth Science Tech, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1538495 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.1%
TTM net income YoY33.6%
TTM EPS YoY-7.7%
Revenue 3-yr CAGR149.7%
Net income 3-yr CAGR144.1%

Margins

Gross margin70.2%
Operating margin—
Net margin11.0%
FCF margin2.2%
EBITDA margin—

Returns

ROE57.5%
ROA38.5%
ROIC (approx.)—
Asset turnover3.50x

Leverage & solvency

Liabilities / assets25.6%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.43x
Accruals ratio22.0%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$35.70M$33.12M$11.95M$48,537$14,123
Cost of revenue$10.21M$8.82M$4.13M$26,477$22,639
Gross profit$25.49M$24.30M$7.83M$22,060-$8,516
R&D expense———$0$0
SG&A expense$3.57M$4.15M$166,976$231,890$116,064
Operating income——$892,349-$936,683-$226,706
Interest expense$16,327$21,189$4,125$47,433$86,706
Pretax income$3.09M$3.37M$825,142-$365,405$3.17M
Income tax-$511,676$116,776$13,003——
Net income$3.63M$3.25M$812,139-$365,405$3.17M
EBITDA——$1.04M-$919,192-$226,706
EPS (basic)0.010.010.00-0.000.06
EPS (diluted)0.010.010.00-0.00—
Weighted avg. shares (diluted)293.07M303.52M309.69M145.87M—
Banking
Net interest income—-$21,189-$67,207-$47,433—
Balance sheet
Cash & equivalents$796,797$1.47M$697,721$35,756$26,942
Receivables$356,054$129,064$235,423$0—
Inventory$682,059$503,938$315,738$10,260—
Current assets$3.72M$3.11M$1.26M$46,016$26,942
PP&E, net$1.52M$1.38M$135,352$143,213—
Goodwill$2.65M$2.30M$2.30M$2.30M—
Intangibles$208,170$96,885$28,441$35,276—
Total assets$8.97M$7.07M$3.88M$2.73M$76,942
Current liabilities$1.93M$3.15M$1.49M$1.31M$1.88M
Short-term debt—$179,488$30,592$604,767$780,694
Long-term debt——$60,559$204,408$780,694
Total debt——$91,151$809,175$1.56M
Total liabilities$1.93M$3.22M$1.63M$1.61M$1.88M
Shareholders' equity$7.01M$3.85M$2.25M$1.12M-$1.81M
Net debt——-$606,570$773,419$1.53M
Shares outstanding291.32M294.30M309.98M282.61M53.85M
Cash flow statement
Operating cash flow$1.94M$4.37M$1.21M-$1.01M-$168,106
Capital expenditure$756,619$753,165$26,520——
Free cash flow$1.18M$3.62M$1.18M——
Investing cash flow-$1.90M-$1.88M-$26,520—$1,712
Financing cash flow-$712,917-$1.72M-$517,886$1.02M$173,175
Depreciation & amortization$284,396$53,951$149,749$17,491$0
Stock-based compensation——$300$4,500—
Share buybacks$471,410$1.47M$178,000——

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.